Bayer

Finerenone approved in Japan for treatment of patients with chronic heart failure

22 Dec 2025

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

17 Dec 2025

Aflibercept 8 mg recommended for EU approval for third retinal indication

15 Dec 2025

AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan

09 Dec 2025

MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome

04 Dec 2025

Data from Pediatric Study for Bayer's Investigational MRI Contrast Agent presented at RSNA 2025

04 Dec 2025

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia

03 Dec 2025

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

23 Nov 2025

U.S. FDA grants accelerated approval to Bayer’s HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant non-small cell lung cancer

20 Nov 2025

Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer

19 Nov 2025

View details about the software product Informachine News Trackers